NIH Honcho: ‘Impossible’ To Predict COVID Vaccine By November

WASHINGTON, DC - JULY 2: Dr. Francis Collins, Director of the National Institutes of Health (NIH), testifies during a US Senate Appropriations subcommittee hearing on the plan to research, manufacture and distribute ... WASHINGTON, DC - JULY 2: Dr. Francis Collins, Director of the National Institutes of Health (NIH), testifies during a US Senate Appropriations subcommittee hearing on the plan to research, manufacture and distribute a coronavirus vaccine, known as Operation Warp Speed, July 2, 2020 on Capitol Hill in Washington, DC. (Photo by Saul Loeb-Pool/Getty Images) MORE LESS
|
September 9, 2020 11:49 a.m.

It’s impossible to know if there will be a safe and effective vaccine by November, National Institutes of Health Director Francis Collins told the Senate on Wednesday morning.

“Will it be done by a certain date? I could not possibly tell you right now,” Dr. Collins told Sen. Bernie Sanders (D-VT) during a hearing of the Senate health committee. “Certainly, to try to predict whether it happens on a particular week before or after a particular date in early November is well beyond anything that any scientist right now could tell you and know what they’re saying.”

Collins added that “science and science alone will lead the way. Otherwise, I’ll have no part of it.”

As head of NIH, Collins does not play a direct role in approving an eventual COVID-19 vaccine.

Newsletters
Get TPM in your inbox, twice weekly.
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Rather, that task falls to the Food and Drug Administration, which is overseeing three COVID-19 vaccines that are currently in mass, phase III trials.

President Trump has been pressuring the FDA to approve a vaccine before the November election in a bid to juice his re-election chances. Some of the President’s advisors have reportedly referred to a pre-election vaccine as a “holy grail” for President Trump’s re-election prospects.

Several states have told TPM that they would refuse to distribute a vaccine that did not complete phase III trials or which did not pass muster under review from an independent board of scientists.

Collins added, “I don’t know what is going to happen.”

“I do have cautious optimism that by the end of 2020, one of these vaccines will have emerged and turned out to be safe and effective,” he added.

Latest Muckraker
Comments are now Members-Only

Non-members are still able to read comments, but will no longer be able to participate. To join the conversation, sign up now and get:

30% Off Annual Prime Membership

TPM strives to build as inclusive a community as financially possible. We offer FREE memberships to those experiencing financial hardship and FREE memberships for students.

View all options
Comments
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Reporters:
Newswriters:
Audience Development Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: